Upstream Bio to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) announced CEO Rand Sutherland will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston on March 4 (Fireside Chat at 9:50 a.m. ET) and Leerink Partners Global Healthcare Conference in Miami on March 9 (Fireside Chat at 1:40 p.m. ET).
Live webcasts will be available under the Events tab on the Investors section of Upstream Bio’s website, and replays will be posted after the presentations.
Positive
- None.
Negative
- None.
Details
News Market Reaction – UPB
In the Feb 25 session, UPB declined 2.27%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- TD Cowen conference edition
- 46th Annual
- TD Cowen 46th Annual Health Care Conference
- TD Cowen fireside date
- March 4, 2026
- TD Cowen Health Care Conference fireside chat date
- TD Cowen fireside time
- 9:50 a.m. ET
- Scheduled time for TD Cowen fireside chat
- Leerink fireside date
- March 9, 2026
- Leerink Partners Global Healthcare Conference fireside chat date
- Leerink fireside time
- 1:40 p.m. ET
- Scheduled time for Leerink Partners fireside chat
Historical Context
-
Positive VALIANT Phase 2 severe asthma data with strong AAER reductions.
-
Announcement of webcast to present upcoming VALIANT Phase 2 top-line results.
-
Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference.
-
Participation in two December 2025 healthcare investor conferences with webcasts.
-
Q3 2025 financials plus positive Phase 2 VIBRANT results and pipeline progress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March:
- TD Cowen 46th Annual Health Care Conference, Boston, MA
Wednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET - 2026 Leerink Partners Global Healthcare Conference, Miami, FL
Monday, March 9, 2026, Fireside Chat - 1:40 p.m. ET
Live webcasts of the presentations will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay of the webcasts will be posted on the Company's website following the presentations.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.